Related Experiment Video
Updated: Aug 5, 2026
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and
Jiangzhuo Wu1,2, Hanbing Li1,2, Ling Wei1,2
1Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Background:
Breast cancer, as a prevalent malignant tumor among women worldwide, has its malignant progression closely linked to angiogenesis mechanisms. Research indicates that combining anti-angiogenic drugs can promote tumor vascular normalization, thereby improving the delivery of chemotherapeutic agents and reversing the drug-resistant microenvironment. Some clinical studies have confirmed that such combination regimens can enhance pathological response rates (pCR). This paper aims to systematically evaluate the clinical value of angiogenesis inhibitors in neoadjuvant chemotherapy (NACT) for breast cancer and provide evidence-based guidance to optimize treatment strategies.
Methods:
We systematically searched the PubMed and Web of Science databases up to July 16, 2025, to identify randomized controlled trials (RCTs) comparing angiogenesis inhibitor-based NACT regimens with angiogenesis inhibitor-free regimens in breast cancer patients. Using random effects models, we calculated pooled odds ratios and hazard ratios with 95% confidence intervals for pCR, disease-free survival (DFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs).
Results:
This analysis included 10 RCTs (8,069 patients). The results showed that NACT containing angiogenesis inhibitors significantly increased the pCR rate (22.59% vs. 29.88%). Subgroup analysis indicated no statistically significant improvement in pCR among hormone receptor-positive patients, whereas in triple-negative breast cancer (TNBC), the pCR rate was significantly elevated (32.42% vs. 42.46%). Regarding survival outcomes, no significant differences were observed in either DFS or OS.
Conclusions:
The combination of bevacizumab with NACT can improve the pCR rate, with this effect being particularly pronounced in TNBC. However, current research has not yet reached a consensus on whether it can improve OS, and there remains a lack of clear biomarkers for predicting treatment efficacy.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261411787.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...